IDYAIDEAYA BiosciencesSigning up patients
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Uveal Melanoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 450 (planned)
- Started
- Sep 2026
- Main results expected
- Mar 2034
- Fully finished
- Apr 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Median relapse-free survival
Measured over: Approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07804186 · record last updated 2026-09-15 · checked 2026-11-09 15:36 UTC